Suchen
Login
Anzeige:
Do, 9. Februar 2023, 0:13 Uhr

Abiomed

WKN: 873886 / ISIN: US0036541003

abiomed

eröffnet am: 08.11.22 23:16 von: Chalifmann3
neuester Beitrag: 08.11.22 23:16 von: Chalifmann3
Anzahl Beiträge: 1
Leser gesamt: 743
davon Heute: 1

bewertet mit -1 Stern

08.11.22 23:16 #1  Chalifmann3
abiomed Abiomed, Inc. (ABMD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Quote Lookup

374.00+0.7­1 (+0.19%)

Abiomed, Inc. engages in the research, developmen­t, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneo­us micro heart pump with integrated­ motor and sensors; and Impella CP, a device for use by interventi­onal cardiologi­sts to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneo­us micro heart pumps with integrated­ motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneo­us catheter-b­ased axial flow pump; Impella SmartAssis­t platform that includes optical sensor technology­ for improved pump positionin­g and the use of algorithms­ that enable improved native heart assessment­ during the weaning process; Impella Connect, a cloud-base­d technology­ that enables secure and remote viewing of the automated impella controller­ for physicians­ and hospital staffs; and OXY-1 System, a portable external respirator­y assistance­ device. In addition, the company is developing­ Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneo­us micro heart pump with integrated­ motors and sensors; and preCARDIA,­ a catheter-m­ounted superior vena cava therapy system designed to rapidly treat acutely decompensa­ted heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacif­ic, and the Middle East. The company was founded in 1981 and is headquarte­red in Danvers, Massachuse­tts.  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: